Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Mivebresib||ABBV-075||BET Inhibitor (Pan) 30||Mivebresib (ABBV-075) is a bromodomain (BET) inhibitor, which may disrupt transcriptional regulation and lead to apaotosis of tumor cells (PMID: 28416490, PMID: 31420359).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Mivebresib||Preclinical - Patient cell culture||Actionable||In a preclinical study, Mivebresib (ABBV-075) induced apoptosis and inhibited growth of acute myeloid leukemia (AML) cell lines and patient-derived cells in culture, and inhibited tumor growth in an AML cell line xenograft model (PMID: 28416490).||28416490|
|Unknown unknown||multiple myeloma||not applicable||Mivebresib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with Mivebresib (ABBV-075) altered expression of ZCCHC24, HEXIM1, SERPINI1, and MYC in a multiple myeloma cell line in culture and in xenograft models, and these changes correlated with inhibition of proliferation in culture and inhibition of tumor growth in xenograft models (PMID: 27903752).||27903752|
|Unknown unknown||Advanced Solid Tumor||not applicable||Mivebresib||Phase I||Actionable||In a Phase I trial, Mivebresib (ABBV-075) treatment demonstrated safety and modest clinical activity, resulted in stable disease as best response in 43% (26/61) of evaluable patients with advanced solid tumors, with a median progression-free survival of 1.8 months (PMID: 31420359; NCT02391480) .||31420359|
|Unknown unknown||uveal melanoma||not applicable||Mivebresib||Phase I||Actionable||In a Phase I trial, Mivebresib (ABBV-075) treatment demonstrated safety and modest clinical activity in patients with uveal melanoma, resulting in stable disease as best response in 44% (4/9) of evaluable patients, patients achieved stable disease had lower cfDNA mutational load of pathogenic mutations (53.1 vs 893.9 median mutant molecules/mL plasma) compared to patients developed progressive disease (J Clin Oncol 37, no. 15_suppl; NCT02391480).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04480086||Phase I||Mivebresib + Navitoclax Mivebresib + Ruxolitinib Mivebresib||Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis||Recruiting||USA||11|
|NCT02391480||Phase I||Mivebresib||A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer||Completed||USA||0|